Novo Nordisk said a higher dose of its drug Wegovy led to greater weight loss in patients during a late-stage trial, but the ...

The changes reflect “a cultural shift” around obesity medications, said Diana Zuckerman, president of the nonprofit National ...

U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that ...

The U.S. government on Friday announced a list of 15 prescription medicines targeted for Medicare price negotiations for 2027 ...

CNBC's Angelica Peebles talks to Structure Therapeutics CEO Ray Stevens about the obesity landscape and why there's still ...

In a rare move, the FDA recommended a minimum of 5% weight-loss for drug developers seeking to establish the efficacy of ...

The popularity of GLP-1R drugs has catapulted the treatment landscape of obesity into the spotlight. Reformation for the ...

Ozempic and Wegovy, the blockbuster but costly GLP-1 drugs often used for weight loss, are among the 15 medications that will ...

Deloitte notes that many companies are trying to capture a share of the $200 billion GLP-1 drug market. Beyond obesity, potential indications for these drugs include sleep apnea, addiction ...

Using body-mass index to tell who is overweight or obese is not reliable and can result in misdiagnosis, the Commission on ...

Diabetes and weight loss drugs Ozempic and Wegovy have been added to the list of medications selected for Medicare price ...